Home » Topics » Regulatory » EMA

EMA
RSS

Ariad's AP-24534 receives orphan drug status for CML

March 2, 2010

COMP grants perifosine positive opinion as orphan medicinal product in MM

March 2, 2010

EMA approves OncoGenex's development plan for OGX-011

Feb. 26, 2010

Rare Disease Day 2010 focuses attention on orphan drug development

Feb. 26, 2010

CHMP adopts positive opinion on marketing of GSK's pandemic influenza vaccine Arepanrix

Jan. 28, 2010

CHMP recommends suspension of marketing authorization for sibutramine

Jan. 26, 2010

EMEA recommends additional measures to manage risk for PML with Tysabri therapy

Jan. 26, 2010

Janssen-Cilag notifies EMEA of withdrawal of Comfyde MAA for partial-onset seizures

Jan. 26, 2010

EMEA recommends withdrawal of benfluorex from the market in E.U.

Dec. 28, 2009

Bayer Schering withdraws European MAA for Recothrom (thrombin alfa)

Dec. 16, 2009

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...